Jiangsu Hengrui Pharmaceuticals Co Ltd, a global pharmaceutical company focusing on scientific and technological innovation, announced on March 25 that it has entered into an exclusive license ...

Pfizer and AbbVie shares declined more than 4%, Merck dropped almost 4%, and Eli Lilly pulled back over 3% in early trading. Daily Merck & Company, Inc. Dow pharmaceutical components are leading ...

Lusaka [Zambia] / Mumbai (Maharashtra) [India], April 7: Merck Foundation, the philanthropic arm of Merck KGaA Germany marks 'World Health Day' 2025 in partnership with Africa's First Ladies who ...

Merck has shared data from the pivotal 3475A-D77 Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together with berahyaluronidase alfa (subcutaneous pembrolizumab). The study ...

Mer­ck KGaA is spend­ing $85 mil­lion to tap glob­al com­mer­cial­iza­tion rights to pim­i­co­tinib, a can­di­date for non-ma­lig­nant tu­mors that it li­censed from Chi­na’s ...

This year's two sessions is a reconfirmation of the confidence that Merck has in China because the Chinese government has set the economic growth target at 5 percent, focusing more on innovation ...

Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia. The ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s patent cliff at bay. In a push to keep the Keytruda gravy train on the ...

German life sciences and pharma company Merck KGaA (MRK: DE) today revealed it has exercised its option with China’s Abbisko Therapeutics (HKEX: 02256) for commercialization of pimicotinib in the US ...

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the Greater China region. Hengrui Pharma will ...

Mer­ck shared Phase 3 da­ta show­ing that an in­jectable ver­sion of its block­buster can­cer drug Keytru­da is com­pa­ra­ble to the ap­proved … ...